Toggle Side Panel
Close search

Potential IPF Therapy PXS-5382A Shows Potential in Phase 1 Trial

  • Research and Development

    Potential IPF Therapy PXS-5382A Shows Potential in Phase 1 Trial

    Posted by Community Member on December 6, 2018 at 11:32 am

    Phase 1 data show that Pharmaxis’ second LOXL2 inhibitor, PXS-5382A, is safe and holds potential to treat fibrotic diseases, including IPF. Click here to find out more.

    Did you know about this potential treatment? What are your thoughts on it?

    Community Member replied 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.

Start of Discussion
0 of 0 replies June 2018
Now

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .